Blepharitis risk factors: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 17: | Line 17: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Infectious disease]] | |||
[[Category:Ophthalmology]] | |||
[[Category:Primary care]] | [[Category:Primary care]] | ||
Revision as of 15:30, 8 August 2016
|
Blepharitis Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Blepharitis risk factors On the Web | |
|
American Roentgen Ray Society Images of Blepharitis risk factors | |
|
Risk calculators and risk factors for Blepharitis risk factors | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [2]
Overview
Common risk factors for the development of blepharitis include dry eye, acne rosacea, seborrheic dermatitis, and demodicosis.
Risk factors
Risk factors for the development of blepharitis include:
- Dry eye[1]
- Dermatologic conditions (acne rosacea, seborrheic dermatitis)[2]
- Demodicosis[3]
- Isotretinoin[4][5]
- Giant papillary conjunctivitis[6]
References
- ↑ Bowman RW, Dougherty JM, McCulley JP (1987). "Chronic blepharitis and dry eyes". Int Ophthalmol Clin. 27 (1): 27–35. PMID 3818198.
- ↑ McCulley JP, Dougherty JM (1985). "Blepharitis associated with acne rosacea and seborrheic dermatitis". Int Ophthalmol Clin. 25 (1): 159–72. PMID 3156100.
- ↑ Kemal M, Sumer Z, Toker MI, et al. The prevalence of Demodex folliculorum in blepharitis patients and the normal population. Ophthalmic Epidemiol 2005;12:287-90.
- ↑ McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology 1982;89:1173-80.
- ↑ Bozkurt B, Irkec MT, Atakan N, et al. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. Eur J Ophthalmol 2002;12:173-6.
- ↑ Martin NF, Rubinfeld RS, Malley JD, Manzitti V. Giant papillary conjunctivitis and meibomian gland dysfunction blepharitis. CLAO J 1992;18:165-9.